![Michael Kelliher](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Michael Kelliher
Direktor/Vorstandsmitglied bei CAPRICOR THERAPEUTICS, INC.
Vermögen: 1 Mio $ am 31.05.2024
Profil
Michael Kelliher is currently an Independent Director at Capricor Therapeutics, Inc. since 2023 and an Executive VP-Corporate Development & Strategy at Ardelyx, Inc. since 2024.
Previously, he worked as a Group Vice President-Merger & Acquisition at Horizon Therapeutics Plc.
He completed his undergraduate degree at University College Cork.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
ARDELYX, INC.
0,07% | 25.03.2024 | 160 000 ( 0,07% ) | 1 Mio $ | 31.05.2024 |
18.03.2024 | 0 ( -.--% ) | - $ | 31.05.2024 |
Aktive Positionen von Michael Kelliher
Unternehmen | Position | Beginn |
---|---|---|
CAPRICOR THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.09.2023 |
ARDELYX, INC. | Corporate Officer/Principal | 25.03.2024 |
Ehemalige bekannte Positionen von Michael Kelliher
Unternehmen | Position | Ende |
---|---|---|
HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Corporate Officer/Principal | - |
Ausbildung von Michael Kelliher
University College Cork | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
CAPRICOR THERAPEUTICS, INC. | Health Technology |
ARDELYX, INC. | Health Technology |
Private Unternehmen | 1 |
---|---|
Horizon Therapeutics Plc
![]() Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |